GEN News Highlights

Partners will use Horizon’s rAAV platform to generate mouse models and to investigate genetics of cancer drug resistance.[Gernot Krautberger-Fotolia.com]

(Page
1
of
1)

Horizon Discovery and the Fox Chase Cancer Center are establishing a center of excellence in gene editing as part of a three-year collaboration focused both on the application of Horizon’s rAAV gene-targeting technology in mouse embryonic stem cells and the discovery of genes involved in human cancer resistance to EGFR-targeted therapies.

The collaboration will generate both new human isogenic disease models and mouse knockout models licensed exclusively to Horizon. The firm will also have an exclusive option to license new IP originating from the partnership. It says the partnership will aid its drive to develop at least 2,500 new X-Man™ models of cancer, neurodegenerative, and cardiovascular diseases.

The Center of Excellence will work to expand the applications of rAAV gene editing to in vivo mouse models for applications in functional genomics and translational medicine. The cancer-resistance research aims to identify genes involved in the mechanisms by which some tumors are resistant to drugs such as Erbitux and Vectibix, and potentially identify novel targets for treatment.

“These efforts will allow us to more realistically model how combining new signaling inhibitors affects certain drug-resistant cancers,” comments Jonathan Chernoff, Ph.D., CSO at Fox Chase. “In addition, if we are able to use rAAV technology to modify mouse ES cells, this could open the door to rapid, high-throughput gene editing in the mouse.”

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

Be sure to take the GEN Poll

Climate Change

How would you describe the researchers response to the 2°C global temperature target?

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

38.9%

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

22.2%

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.